Cardiff Oncology, Inc. — Director's Dealing 2021

Jun 14, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cardiff Oncology, Inc. (CRDF)
CIK: 0001213037
Period of Report: 2021-06-10

Reporting Person: Erlander Mark (Director, Chief Executive Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-06-10	Stock Options	$7.98	A	435072	Acquired	2031-06-10	Common Stock (435072.0)	Direct

Footnotes

F1: 108,768 vest on 6/10/2022. 9,064 vest monthly for 36 months beginning on 7/10/2022 through 6/10/2025.